Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H13N3O · 0.5H2SO4
CAS Number:
Molecular Weight:
240.27
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12161501
MDL number:
Form:
solid
Quality level:
InChI
1S/2C10H13N3O.H2O4S/c2*11-10(12)13-5-7-3-1-2-4-8(7)9(14)6-13;1-5(2,3)4/h2*1-4,9,14H,5-6H2,(H3,11,12);(H2,1,2,3,4)
SMILES string
OS(O)(=O)=O.NC(=N)N1CC(O)c2ccccc2C1.NC(=N)N3CC(O)c4ccccc4C3
InChI key
AETJLQVZNVTWPH-UHFFFAOYSA-N
form
solid
color
off-white
mp
267 °C
storage temp.
2-8°C
Quality Level
Related Categories
Application
(±)-4-Hydroxydebrisoquin sulfate can be used for the metabolic studies of debrisoquin.
Biochem/physiol Actions
CYP2D6 metabolite of debrisoquin.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R Ismail et al.
Journal of clinical pharmacy and therapeutics, 25(5), 379-383 (2000-12-21)
Although they originated from China, Malays have undergone a lot of intermarriages. A study suggested that CYP2D6 poor metabolism (PM) phenotype was more common in Malays compared to Chinese. CYP2D6 is highly polymorphic and is involved in the metabolism of
Miki Katoh et al.
Journal of pharmaceutical sciences, 96(2), 428-437 (2006-10-20)
We previously clarified that major human drug metabolizing enzymes were expressed in a chimeric urokinase-type plasminogen activator (uPA)+/+/severe combined immunodeficient (SCID) mouse line established recently, in which the liver could be replaced by more than 80% with human hepatocytes. In
M J Steiger et al.
Acta neurologica Scandinavica, 86(2), 159-164 (1992-08-01)
Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. There was no significant difference between the proportion of poor metabolisers of DBQ among YOPD patients
A Bozkurt et al.
Journal of pharmaceutical and biomedical analysis, 11(8), 745-749 (1993-08-01)
A simple, selective and sensitive method has been developed to determine debrisoquine and 4-hydroxydebrisoquine in human urine. Separation of the analytes was obtained using a mobile phase of 0.1 M sodium dihydrogen phosphate-acetonitrile (87:13, v/v) and a muBondapak C18 column.
P M Cerqueira et al.
Journal of chromatography. B, Biomedical sciences and applications, 749(2), 153-161 (2001-01-06)
Debrisoquine (D), an antihypertensive drug metabolized to 4-hydroxydebrisoquine (4-OHD) by CYP2D6, is commonly used as an in vivo probe of CYP2D6 activity and can be used to phenotype individuals as either extensive (EMs) or poor metabolizers (PMs) of such drugs
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service